Fiche publication
Date publication
avril 2021
Journal
The oncologist
Auteurs
Membres identifiés du Cancéropôle Est :
Dr THIERY-VUILLEMIN Antoine
Tous les auteurs :
Thiery-Vuillemin A, Fizazi K, Sartor O, Oudard S, Bury D, Ozatilgan A, Poole EM, Eisenberger M, de Bono J
Lien Pubmed
Résumé
The phase III PROSELICA (NCT01308580) and FIRSTANA (NCT01308567) trials investigated taxane chemotherapy among men with post-docetaxel metastatic castration-resistant prostate cancer (mCRPC) or chemotherapy-naïve mCRPC, respectively. We present a post hoc analysis of patient reported health-related quality of life (HRQL) among patients with or without a clinical (pain, tumor or prostate-specific antigen [PSA]) response.
Mots clés
HRQL, Prostate, cabazitaxel, docetaxel, mCRPC, pain
Référence
Oncologist. 2021 Apr 27;:
